Daclizumab in live donor renal transplantation

Iverson, Alan J.; Vick, Sherell; Sarnacki, Clifford T.; Wright, Francis H.

doi:10.1016/s0041-1345(00)00984-2

Cited by 4 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another nonrandomized trial evaluating the combination of daclizumab with MMF/steroids/CNI (CsA-ME or TAC), Iverson and colleagues compared 58 patients (64% Hispanic) who received living donor renal allografts with a matched cohort of 27 patients. 33 The four-month BPAR rate was 7% in daclizumab-treated patients vs 15% in control patients. There were no differences in the rate of adverse events, graft, and patient survival.…”

Section: Il-2ra With Mmf And/or Tacmentioning

confidence: 92%

“…In concert with the introduction of newer and more potent maintenance immunosuppressive medication, basiliximab and daclizumab were evaluated in different immunosuppressive protocols. 26,[33][34][35][36][37][38] In a short report of a blind randomized trial, 75 patients treated with maintenance immunosuppression consisting of CsA, MMF, and steroids were administered daclizumab or placebo. 39 There was a six-month BPAR rate of 12% in daclizumab-treated patients as compared with 20% in those receiving placebo.…”

Section: Il-2ra With Mmf And/or Tacmentioning

confidence: 99%

See 1 more Smart Citation

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation

Sageshima¹,

Burke²,

Ciancio³

et al. 2009

BTT

View full text Add to dashboard Cite

The use of antibody induction after kidney transplantation has increased from 25% to 63% in the past decade and roughly one half of the induction agent used is antiinterleukin-2 receptor antibody (IL-2RA, ie, basiliximab or daclizumab). When combined with calcineurin inhibitor (CNI)-based immunosuppression, IL-2RAs have been shown to reduce the incidence of acute rejection, one of the predictors of poor graft survival, without increasing risks of infections and malignancies in kidney transplantation. For low-immunological-risk patients, IL-2RAs, as compared with lymphocyte-depleting antibodies, are equally efficacious and have better safety profiles. For high-risk patients, however, IL-2RAs may be inferior to lymphocyte-depleting antibodies for the prophylaxis of acute rejection. In an effort to reduce toxicities of other immunosuppressive medications without increasing the risk of acute rejection and chronic graft loss, IL-2RAs have often been combined with steroid-and CNI-sparing immunosuppression protocols. More data support the benefits of early steroid withdrawal with IL-2RA in low-risk patients, but preferred induction therapy for high-risk patients has yet to be determined. Although CNI-sparing protocols with IL-2RA may preserve renal function and improve long-term survival in selected patients, further studies are needed to identify those who benefit most from this strategy.

show abstract

Section: Il-2ra With Mmf And/or Tacmentioning

confidence: 92%

Section: Il-2ra With Mmf And/or Tacmentioning

confidence: 99%

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation

Sageshima¹,

Burke²,

Ciancio³

et al. 2009

BTT

View full text Add to dashboard Cite

show abstract

“…In concert with the introduction of newer and more potent maintenance immunosuppressive medication, basiliximab and daclizumab were evaluated in different immunosuppressive protocols 26,33–38. In a short report of a blind randomized trial, 75 patients treated with maintenance immunosuppression consisting of CsA, MMF, and steroids were administered daclizumab or placebo 39.…”

Section: Il-2ra With Mmf And/or Tacmentioning

confidence: 99%

“…The combination of daclizumab and maintenance triple therapy with MMF was safe, well tolerated, and demonstrated low incidence of acute rejection. In another nonrandomized trial evaluating the combination of daclizumab with MMF/steroids/CNI (CsA-ME or TAC), Iverson and colleagues compared 58 patients (64% Hispanic) who received living donor renal allografts with a matched cohort of 27 patients 33. The four-month BPAR rate was 7% in daclizumab-treated patients vs 15% in control patients.…”

Section: Il-2ra With Mmf And/or Tacmentioning

confidence: 99%

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation

Sageshima

Ciancio

Chen

et al. 2009

BTT

View full text Add to dashboard Cite

The use of antibody induction after kidney transplantation has increased from 25% to 63% in the past decade and roughly one half of the induction agent used is anti-interleukin-2 receptor antibody (IL-2RA, ie, basiliximab or daclizumab). When combined with calcineurin inhibitor (CNI)-based immunosuppression, IL-2RAs have been shown to reduce the incidence of acute rejection, one of the predictors of poor graft survival, without increasing risks of infections and malignancies in kidney transplantation. For low-immunological-risk patients, IL-2RAs, as compared with lymphocyte-depleting antibodies, are equally efficacious and have better safety profiles. For high-risk patients, however, IL-2RAs may be inferior to lymphocyte-depleting antibodies for the prophylaxis of acute rejection. In an effort to reduce toxicities of other immunosuppressive medications without increasing the risk of acute rejection and chronic graft loss, IL-2RAs have often been combined with steroid- and CNI-sparing immunosuppression protocols. More data support the benefits of early steroid withdrawal with IL-2RA in low-risk patients, but preferred induction therapy for high-risk patients has yet to be determined. Although CNI-sparing protocols with IL-2RA may preserve renal function and improve long-term survival in selected patients, further studies are needed to identify those who benefit most from this strategy.

show abstract

Induction Therapy in Renal Transplantation

Ciancio

Burke

Miller

2007

Drugs

View full text Add to dashboard Cite

An overview of the past 10 years of clinical renal transplantation would include progress in the development of new induction protocols (non-depleting versus depleting monoclonal and polyclonal antibodies, plasmapheresis and intravenous immunoglobulins) designed to reduce the incidence and severity of rejection and adverse effects as well as improve long-term graft and patient survival. These modalities have been introduced primarily to reduce the incidence of acute rejection episodes leading to early graft loss, decrease the need for higher toxic doses of maintenance immunosuppressive drugs, such as calcineurin inhibitors, and possibly aid in the pursuit of the goal of achieving immunological tolerance and the avoidance of all long-term immunosuppressive therapy. What has resulted during the past 20 years as the use of induction agents has become more popular is the concurrent improvement in detection and treatment of acute and chronic infectious (primarily viral), and opportunistic and quasi-malignant disease accompanying the use of these agents and, therefore, their increase in popularity. However, the overall cost of therapy and the long-term results of protocols in which these agents have been used have not resulted in a definitive benefit thus far, because of the lack of sufficient numbers of defined randomised, long-term studies and the continuing introduction of newer protocols based on even more recent advances. The specific agents used for induction therapy to date, and the rationale for their introduction and mechanisms of action are discussed in this review.

show abstract

Daclizumab in live donor renal transplantation

Cited by 4 publications

References 4 publications

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation

Induction Therapy in Renal Transplantation

Contact Info

Product

Resources

About

Daclizumab in live donor renal transplantation

Cited by 4 publications

References 4 publications

Anti-interleukin-2 receptor antibodies&mdash;basiliximab and daclizumab&mdash;for the prevention of acute rejection in renal transplantation

Anti-interleukin-2 receptor antibodies&mdash;basiliximab and daclizumab&mdash;for the prevention of acute rejection in renal transplantation

Anti-interleukin-2 receptor antibodies&mdash;basiliximab and daclizumab&mdash;for the prevention of acute rejection in renal transplantation

Induction Therapy in Renal Transplantation

Contact Info

Product

Resources

About

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation